Last reviewed · How we verify
G-CHOP
G-CHOP is a chemotherapy regimen combining gemcitabine, cyclophosphamide, doxorubicin, and vincristine (Oncovin) to kill rapidly dividing cancer cells through multiple cytotoxic mechanisms.
G-CHOP is a chemotherapy regimen combining gemcitabine, cyclophosphamide, doxorubicin, and vincristine (Oncovin) to kill rapidly dividing cancer cells through multiple cytotoxic mechanisms. Used for Lymphoma (likely non-Hodgkin lymphoma or Hodgkin lymphoma).
At a glance
| Generic name | G-CHOP |
|---|---|
| Sponsor | Nanjing Yoko Biomedical Co., Ltd. |
| Drug class | Chemotherapy combination regimen |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
G-CHOP is a polychemotherapy combination where gemcitabine acts as an antimetabolite, cyclophosphamide and doxorubicin are alkylating agents and topoisomerase II inhibitors respectively, and vincristine is a microtubule inhibitor. Together, these agents target different phases of the cell cycle and DNA synthesis to induce apoptosis in malignant cells, commonly used in lymphoma treatment.
Approved indications
- Lymphoma (likely non-Hodgkin lymphoma or Hodgkin lymphoma)
Common side effects
- Myelosuppression (neutropenia, anemia, thrombocytopenia)
- Nausea and vomiting
- Alopecia
- Mucositis
- Cardiotoxicity (doxorubicin-related)
- Peripheral neuropathy (vincristine-related)
Key clinical trials
- Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (PHASE3)
- A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010) (PHASE3)
- Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma (PHASE3)
- Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma (PHASE1)
- Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphomas (PHASE1)
- Evaluation of Treatment by Glofitamab in Combination With Rituximab or Obinutuzumab Plus CHOP in Patients With RIchter Syndrome (PHASE2)
- Comparison Study of EAP and Disease-Specific Chemotherapy Regimens in Hematopoietic Stem Cell Mobilization for Lymphoma (PHASE3)
- Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular Lymphoma (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- G-CHOP CI brief — competitive landscape report
- G-CHOP updates RSS · CI watch RSS
- Nanjing Yoko Biomedical Co., Ltd. portfolio CI